Enzymotec Ltd. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported net revenues of $10,584,000 compared to $13,269,000 a year ago. Operating loss was $4,080,000 compared to operating income of $1,135,000 a year ago. Loss before income taxes was $4,214,000 compared to income before income taxes of $1,087,000 a year ago. Net loss was $4,214,000 or $0.18 per basic and diluted share compared to net income of $1,135,000 or $0.05 per basic and diluted share a year ago. Adjusted LBITDA amounted to $1.4 million, compared to adjusted EBITDA of $2.4 million in the fourth quarter of 2015. Non-GAAP net loss amounted to $2.4 million, or $0.10 per diluted share, compared to non-GAAP net income of $1.6 million in the fourth quarter of 2015. For the year, the company reported net revenues of $47,696,000 compared to $50,391,000 a year ago. The decrease was primarily due to a decrease of $6.7 million in sales of krill products, partially offset by an increase of $2.1 million in sales of INFAT® products and an increase of $2.7 million in sales of VAYA Pharma products. Operating loss was $3,114,000 compared to operating income of $6,174,000 a year ago. Loss before income taxes was $2,857,000 compared to income before income taxes of $6,645,000 a year ago. Net loss was $2,923,000 or $0.13 per basic and diluted share compared to net income of $6,683,000 or $0.29 per diluted share a year ago. Net cash provided by operating activities was $1,385,000 compared to $11,198,000 a year ago. Purchase of property, plant and equipment was $2,114,000 compared to $2,869,000 a year ago. Non-GAAP net income for the year ended December 31, 2016 decreased 86.2% to $1.1 million, or $0.05 per diluted share, from $8.3 million, or $0.36 per diluted share for the year ended December 31, 2015. Adjusted EBITDA was $4,198,000 compared to $10,709,000 a year ago.